<DOC>
	<DOCNO>NCT00001259</DOCNO>
	<brief_summary>This study examine effect estrogen progesterone mood , stress response , brain function behavior woman premenstrual syndrome . Previously study demonstrate leuprolide acetate ( Lupron ( Registered Trademark ) ) effective treatment PMS . The current purpose study evaluate low level estrogen progesterone ( occur treatment leuprolide acetate ) compare menstrual cycle level estrogen progesterone ( give individual month hormone add-back ) variety physiologic measure ( brain imaging , stress testing , etc . ) woman PMS . PMS condition characterize change mood behavior occur second phase normal menstrual cycle ( luteal phase ) . This study investigate possible hormonal cause PMS temporarily stop menstrual cycle leuprolide acetate give , sequence , menstrual cycle hormone progesterone estrogen . The result hormonal study compare woman PMS healthy volunteer without PMS ( see also protocol 92-M-0174 ) . At study entry , participant undergo physical examination . Blood , urine , pregnancy test perform . Cognitive function stress response evaluate study along brain imaging genetic study .</brief_summary>
	<brief_title>A Treatment Study Premenstrual Syndrome ( PMS )</brief_title>
	<detailed_description>This protocol design accompany Clinical Protocol # 81-M-0126 , The Phenomenology Biophysiology Menstrually-Related Mood Behavioral Disorders . Its original purpose follow : 1 ) evaluate efficacy gonadotropin release hormone ( GnRH ) agonist depot leuprolide acetate ( Lupron ) treatment menstrually-related mood disorder ( MRMD ) determine whether mood behavioral symptom eliminate cyclic secretion gonadotropic hormone gonadal steroid suppress , 2 ) determine possible relevance gonadal steroid affective state sequentially replace estradiol progesterone continue GnRH suppression patient whose premenstrual symptom remit follow administration GnRH agonist . We observe GnRH agonist induce ovarian suppression effective treatment compare placebo woman MRMD . Additionally , woman MRMD asymptomatic control ( participate companion protocol 92-M-0174 ) experience recurrence mood behavioral symptom either estradiol progesterone ( placebo ) add back . These data suggest woman MRMD differential sensitivity mood destabilizing effect gonadal steroid . &lt; TAB &gt; Having establish woman MRMD show differential behavioral response estrogen progesterone , hope identify underlying mechanism physiologic concomitant differential behavioral sensitivity perform study ( describe companion protocol ) three hormonal condition create protocol , compare result obtain see normal control ( Protocol # 92-M-0174 ) . Planned study include follow : cognitive testing , brain imaging ( 3D PET , FMRI , MRS ) genetic study include induced pluripotent cell .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA : The subject study woman meet criterion MRMD describe Protocol No . 81M0126 , 'The Phenomenology Biophysiology Menstruallyrelated Mood Behavioral Disorders . ' In brief , criterion include : 1. history within last two year least six month menstruallyrelated mood behavioral disturbance least moderate severityi.e. , disturbance distinct appearance associate notable degree subjective distress ; 2. symptom sudden onset offset ; 3. age 1850 ; 4. pregnant good medical health ; 5. medication free . All patient participate protocol already participate Protocol No . 81M0126 prospectively confirm predictable relationship mood disorder premenstrual phase menstrual cycle , i.e. , 30 % change severity symptom self rating scale , relative range scale employ , seven day premenstrually compare seven day postmenstrually two three month study . The Schedule Affective Disorders Schizophrenia administer patient prior study entry . Any patient current axis I psychiatric diagnosis exclude participate protocol . Prior treatment , complete physical neurological examination perform follow routine laboratory data obtain : A . Blood Complete blood count ; thyroid function test ; cortisol ; renal function test , BUN creatinine ; electrolytes ; glucose ; liver function test . B. Urine Routine urinalysis ; urine pregnancy test . GnRH agonist administer subject significant clinical laboratory abnormality . The blood test urinalysis repeat 2 week GnRH agonist administration rule evidence acute renal , hepatic hematologic toxicity . Results Pap smear perform within one year onset treatment obtain . EXCLUSION CRITERIA : The following condition constitute contraindication treatment hormonal therapy preclude subject 's participation protocol : current Axis I psychiatric diagnosis history consistent endometriosis , diagnosis illdefined , obscure pelvic lesion , particularly , undiagnosed ovarian enlargement , hepatic disease manifest abnormal liver function test , history mammary carcinoma , history pulmonary embolism phlebothrombosis undiagnosed vaginal bleeding porphyria diabetes mellitus history malignant melanoma cholecystitis pancreatitis , cardiovascular renal disease pregnancy Any woman meeting Stages Reproductive Aging Workshop Criteria ( STRAW ) perimenopause . Specifically , exclude woman elevate plasma FSH level ( &gt; = 14 IU/L ) menstrual cycle variability &gt; 7 day different normal cycle length . Subjects take birth control pill exclude study . Subjects take diuretic , prostaglandin inhibitor , pyridoxine ( putative treatment MRMD ) similarly exclude study Patients take psychotropic agent ( e.g. , lithium carbonate , tricyclic antidepressant ) . All subject require use nonhormonal form birth control ( e.g. , barrier method ) avoid pregnancy study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 23, 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Menstrual Cycle</keyword>
	<keyword>Gonadal Steroids</keyword>
	<keyword>GnRH Agonist</keyword>
	<keyword>Mood Disorders</keyword>
</DOC>